Antenatal immunoglobulin for fetal red blood cell alloimmunization

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 5, 2013, Pages

  Wong, Kae Sheen ^a   Connan, Kirsten ^a   Rowlands, Shelley ^a   Kornman, Louise H ^b   Savoia, Helen F ^c  

^a ROYAL WOMEN'S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; MATERNAL ANTIBODY; IMMUNOLOGIC FACTOR;

ANEMIA; ANTIBODY PRODUCTION; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; ERYTHROCYTE DISORDER; ERYTHROCYTE TRANSFUSION; HUMAN; IMMUNE RESPONSE; OUTCOME ASSESSMENT; PHAGOCYTOSIS; PRENATAL PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RED BLOOD CELL ALLOIMMUNIZATION; REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; ANEMIA, HEMOLYTIC; ERYTHROCYTE; FEMALE; FETAL DISEASES; IMMUNOLOGY; PREGNANCY; FETUS DISEASE; HEMOLYTIC ANEMIA;

ANEMIA, HEMOLYTIC; ERYTHROCYTES; FEMALE; FETAL DISEASES; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; PREGNANCY;

EID: 84891702207     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD008267.pub2     Document Type: Review

References (30)

1. Ballow M. Mechanisms of action of intravenous immunoglobulin therapy and potential use in autoimmune connective tissue diseases. Cancer 1991;68:1430-6.
2. Berlin G, Selbing A, Ryden G. Rhesus haemolytic disease treated with high-dose intravenous immunoglobulin. Lancet 1985;1(8438):1153.
3. Cantú TG, Hoehn-Saric EW, Burgess KM, Racusen L, Scheel PJ. Acute renal failure associated with immunoglobulin therapy. American Journal of Kidney Diseases 1995;25(2):228-34.
4. Chitkara U, Bussel J, Alvarez M, Lynch L, Meisel RL, Berkowitz RL. High-dose intravenous gamma globulin: does it have a role in the treatment of severe erythroblastosis fetalis?. Obstetrics & Gynecology 1990;76(4):703-8.
5. Clark A. Clinical uses of intravenous immunoglobulin in pregnancy. Clinical Obstetrics and Gynecology 1999;42(2):368-80.
6. Connan K, Kornman L, Savoia H, Palma-Dias R, Rowlands S. IVIG - Is it the answer? Maternal administration of immunoglobulin for severe fetal red blood cell alloimmunisation during pregnancy: a case series. Australian and New Zealand Journal of Obstetrics and Gynaecology 2009;49:612-8.
7. Deka D, Buckshee K, Kinra G. Intravenous immunoglobulin as primary therapy or adjuvant therapy to intrauterine fetal blood transfusion: a new approach in the management of severe Rh-immunization. Journal of Obstetrics and Gynaecology Research 1996;22(6):561-7.
8. Dooren MC, van Kamp IL, Scherpenisse JW, Brand R, Ouwehand WH, Kanhai HH, et al.No beneficial effect of low-dose fetal intravenous gammaglobulin administration in combination with intravascular transfusions in severe Rh D haemolytic disease. Vox Sanguinis 1994;66(4):253-7.
9. Duhem C, Dicato MA, Ries F. Side-effects of intravenous immune globulins. Clinical and Experimental Immunology 1994;97(Suppl 1):79-83.
10. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315(7109):629-34.
11. Fox C, Martin W, Somerset DA, Thompson PJ, Kilby MD. Early intraperitoneal transfusion and adjuvant maternal immunoglobulin therapy in the treatment of severe red cell alloimmunisation prior to fetal intravascular transfusion. Fetal Diagnosis and Therapy 2008;23:159-63.
12. Geifman-Holtzman O, Wojtowycz M, Kosmas E, Artal R. Female allommunization with antibodies known to cause hemolytic disease. Obstetrics and Gynecology 1997;89(2):272-5.
13. Gottvall T, Selbing A. Alloimmunisation during pregnancy treated with high dose intravenous immunoglobulin. Effects on fetal hemoglobin concentration and anti-D concentrations in the mother and fetus. Acta Obstetricia et Gynecologica Scandinavica 1995;74:777-83.
14. Harbord RM, Egger M, Sterne JA. A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Statistics in Medicine 2006;25(20):3443-57.
15. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
16. Kriplani A, Malhotra Singh B, Mandal K. Fetal intravenous immunoglobulin therapy in rhesus hemolytic disease. Gynecologic and Obstetric Investigation 2007;63(3):176-80.
17. Margulies M, Voto LS, Mathet E, Margulies M. High-dose intravenous IgG for the treatment of severe rhesus alloimmunization. Vox Sang 1991;61(3):181-9.
18. Mari G, Deter RL, Carpenter RL, Rahman F, Zimmerman R, Moise KJ Jr, et al.Noninvasive diagnosis by Doppler ultrasonography of fetal anaemia due to maternal red-cell alloimmunization. New England Journal of Medicine 2000;342(1):9-14.
19. Odendaal HJ, King JB, Oosthuizen OJ. Severe rhesus iso-immunisation successfully treated with apheresis and azathioprine. South African Medical Journal 1986;69(2):122-4.
20. Oepkes D, Seaward PG, Vandenbussche FP, Windrim R, Kingdom J, Beyene J, et al.Doppler ultrasonography versus amniocentesis to predict fetal anemia. New England Journal of Medicine 2006;355(2):156-64.
21. Porter TF, Silver RM, Jackson GM, Branch DW, Scott JR. Intravenous immune globulin in the management of severe Rh D hemolytic disease. Obstetrical & Gynecological Survey 1997;52(3):193-7.
22. Queenan JT, Smith BD, Haber JM, Jeffrey J, Gadow HC. Irregular antibodies in the obstetric patient. Obstetrics and Gynecology 1969;34(6):767-71.
23. Rayment R, Brunskill S, Stanworth S, Soothill PW, Roberts D, Murphy MF. Antenatal interventions for fetomaternal alloimmune thrombocytopenia. Cochrane Database of Systematic Reviews 2005, Issue 1. [DOI: 10.1002/14651858.CD004226.pub2].
24. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
25. Ruma MS, Moise KJ Jr, Kim E, Murtha AP, Prutsman WJ, Hassan SS, et al.Combined plasmapheresis and intravenous immune globulin for the treatment of severe maternal red cell alloimmunization. American Journal of Obstetrics and Gynecology 2007;196(2):138.e1-138.e6.
26. Ulm B, Kirchner L, Svolba G, Jilma B, Deutinger J, Bernaschek G, et al.Immunoglobulin administration to fetuses with anaemia due to alloimmunization to D. Transfusion 1999;39(11-12):1235-8.
27. Van Kamp IL, Klumper FJ, Oepkes D, Meerman RH, Scherjon SA, Vandenbussche FP, et al.Complications of intrauterine intravascular transfusion to fetal anaemia due to maternal red-cell alloimmunization. American Journal of Obstetrics and Gynecology 2005;192:171-7.
28. van Wamelen DJ, Klumper FJ, de Haas M, Meerman RH, van Kamp IL, Oepkes D, et al.Obstetric history and antibody titer in estimating severity of Kell alloimmunization in pregnancy. Obstetrics & Gynecology 2007;109(5):1093-8.
29. Voto LS, Mathet ER, Zapaterio JL, Orti J, Lede RL, Margulies M. High-dose gammaglobulin (IVIG) followed by intrauterine transfusions (IUTs): a new alternative for the treatment of severe fetal haemolytic disease. Journal of Perinatal Medicine 1997;25(1):85-8.
30. Watson WJ, Wax JR, Miller RC, Brost BC. Prevalence of new maternal alloantibodies after intrauterine transfusion for severe rhesus disease. American Journal of Perinatology 2006;23(3):189-92.